Cancer immunotherapy using immune checkpoint inhibitors (ICIs) such as anti-programmed cell death protein 1 (PD-1) drugs or anti-cytotoxic T lymphocytes-associated protein 4 (CTLA-4) drugs have become common in the clinical setting [2]. The gene discussed is CTLA4; the disease is cancer.